Skip to main content
Top
Published in: Digestive Diseases and Sciences 3/2008

01-03-2008 | Original Paper

Treatment Eligibility and Outcomes in Elderly Patients with Chronic Hepatitis C: Results from the VA HCV-001 Study

Authors: Judith I. Tsui, Sue Currie, Hui Shen, Edmund J. Bini, Norbert Brau, Teresa L. Wright, For the VA HCV-001 Study group

Published in: Digestive Diseases and Sciences | Issue 3/2008

Login to get access

Abstract

Objectives We undertook this study to determine if treatment candidacy and outcomes were similar between elderly and non-elderly patients. Methods This was a prospective cohort study that screened 4,025 patients with chronic hepatitis C for HCV antiviral treatment at 24 Veterans Affairs Medical Centers throughout the country. We used multivariable logistic regression to determine whether there was an independent association between being elderly (age > 60 vs. ≤ 60) and (1) being considered a treatment candidate by clinician, and (2) achieving sustained virologic response if treated. Results 364 of the 4,025 patients (9%) were over the age of 60. Only 25% of patients over the age of 60 were considered to be treatment candidates by the evaluating clinician, and only 10% were started on treatment. After adjustment for potential confounders, older age remained associated with a lower likelihood of being considered a treatment candidate (adjusted OR = 0.43; 95% CI: 0.30–0.61). Although based on a small sample of elderly treated patients (n = 35), being elderly did not appear to be associated with a lower likelihood of achieving SVR (adjusted OR = 1.54; 95% CI: 0.46–5.15). Conclusion Among veterans over the age of 60 with chronic hepatitis C who are referred for treatment, relatively few are considered treatment candidates and an even smaller number are ultimately treated. After adjusting for co-morbidities, age remains a strong predictor of not being a treatment candidate. In contrast, older age does not seem to adversely affect treatment outcomes and side effects.
Literature
1.
go back to reference Armstrong GL, Wasley A, Simard EP et al (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144:705–714PubMed Armstrong GL, Wasley A, Simard EP et al (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144:705–714PubMed
2.
go back to reference NIH Consensus Statement on Management of Hepatitis C: (2002) NIH Consens State Sci Statements 19:1–46 NIH Consensus Statement on Management of Hepatitis C: (2002) NIH Consens State Sci Statements 19:1–46
3.
go back to reference Strader DB, Wright T, Thomas DL et al (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147–1171PubMedCrossRef Strader DB, Wright T, Thomas DL et al (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147–1171PubMedCrossRef
4.
go back to reference Marcellin P, Asselah T, Boyer N (2002) Fibrosis and disease progression in hepatitis C. Hepatology 36:S47–S56PubMedCrossRef Marcellin P, Asselah T, Boyer N (2002) Fibrosis and disease progression in hepatitis C. Hepatology 36:S47–S56PubMedCrossRef
5.
go back to reference Poynard T, Ratziu V, Benmanov Y et al (2000) Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis 20:47–55PubMedCrossRef Poynard T, Ratziu V, Benmanov Y et al (2000) Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis 20:47–55PubMedCrossRef
7.
go back to reference Regev A, Schiff ER (2001) Liver disease in the elderly. Gastroenterol Clin North Am 30:547–63, x–xi Regev A, Schiff ER (2001) Liver disease in the elderly. Gastroenterol Clin North Am 30:547–63, x–xi
8.
go back to reference El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745–750PubMedCrossRef El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745–750PubMedCrossRef
9.
go back to reference Bini EJ, Brau N, Currie S et al (2005) Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 100:1772–1779PubMedCrossRef Bini EJ, Brau N, Currie S et al (2005) Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 100:1772–1779PubMedCrossRef
10.
go back to reference Brau N, Bini EJ, Currie S et al (2006) Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin. J Viral Hepat 13:242–249PubMedCrossRef Brau N, Bini EJ, Currie S et al (2006) Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin. J Viral Hepat 13:242–249PubMedCrossRef
11.
go back to reference VA Centers of Excellence in Hepatitis C Research and Education. VA Treatment Recommendations for Patients with Chronic Hepatitis C: version 1.2. 2-25-1999 VA Centers of Excellence in Hepatitis C Research and Education. VA Treatment Recommendations for Patients with Chronic Hepatitis C: version 1.2. 2-25-1999
12.
go back to reference Horiike N, Masumoto T, Nakanishi K et al (1995) Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol 10:246–249PubMed Horiike N, Masumoto T, Nakanishi K et al (1995) Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol 10:246–249PubMed
13.
go back to reference Koyama R, Arase Y, Ikeda K et al (2006) Efficacy of interferon therapy in elderly patients with chronic hepatitis C. Intervirology 49:121–126PubMedCrossRef Koyama R, Arase Y, Ikeda K et al (2006) Efficacy of interferon therapy in elderly patients with chronic hepatitis C. Intervirology 49:121–126PubMedCrossRef
14.
go back to reference Van Thiel DH, Friedlander L, Caraceni P, Molloy PJ, Kania RJ (1995) Treatment of hepatitis C virus in elderly persons with interferon alpha. J Gerontol A Biol Sci Med Sci 50:M330–M333PubMed Van Thiel DH, Friedlander L, Caraceni P, Molloy PJ, Kania RJ (1995) Treatment of hepatitis C virus in elderly persons with interferon alpha. J Gerontol A Biol Sci Med Sci 50:M330–M333PubMed
15.
go back to reference Thabut D, Le Calvez S, Thibault V et al (2006) Hepatitis C in 6,865 patients 65 year or older: a severe and neglected curable disease? Am J Gastroenterol 101:1260–1267PubMedCrossRef Thabut D, Le Calvez S, Thibault V et al (2006) Hepatitis C in 6,865 patients 65 year or older: a severe and neglected curable disease? Am J Gastroenterol 101:1260–1267PubMedCrossRef
16.
go back to reference Nudo C, Gupta S, Alpert E et al Elderly patients are at greater risk for cytopenia during anitviral therapy for hepatitis C. CDDW 2004 abstract, accessed at: http://www.cagacg.org/cddw/cddw2004/abs/abs048.htm Nudo C, Gupta S, Alpert E et al Elderly patients are at greater risk for cytopenia during anitviral therapy for hepatitis C. CDDW 2004 abstract, accessed at: http://​www.​cagacg.​org/​cddw/​cddw2004/​abs/​abs048.​htm
17.
go back to reference Walter LC, Covinsky KE (2001) Cancer screening in elderly patients: a framework for individualized decision making. Jama 285:2750–2756PubMedCrossRef Walter LC, Covinsky KE (2001) Cancer screening in elderly patients: a framework for individualized decision making. Jama 285:2750–2756PubMedCrossRef
Metadata
Title
Treatment Eligibility and Outcomes in Elderly Patients with Chronic Hepatitis C: Results from the VA HCV-001 Study
Authors
Judith I. Tsui
Sue Currie
Hui Shen
Edmund J. Bini
Norbert Brau
Teresa L. Wright
For the VA HCV-001 Study group
Publication date
01-03-2008
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 3/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-007-9926-x

Other articles of this Issue 3/2008

Digestive Diseases and Sciences 3/2008 Go to the issue